NASH Observatory

⏿ The PanNASH Initiative is an interactive web-based platform presenting global NASH statistics to inform NASH control and research.

Getting to the heart of NAFLD/NASH – the CVD perspective

getting-to-the-heart-of-nafld-nash–the-cvd-perspective
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are a leading cause of liver diseases worldwide, including hepatocellular carcinoma (HCC). In this review on non-invasive evaluation, Prof. Jérôme Boursier, France, presents a meta analysis focusing on the identification of patients with high risk profile and in need of specific management. Dr. Boursier reviews the two major families of non-invasive tests and discusses the sequential use of tests recommended in the EASL guidelines 2021.
Read MoreGetting to the heart of NAFLD/NASH – the CVD perspective

NAFLD and MAFLD as emerging causes of hepatocellular carcinoma

Authors: Myers S, Neyroud-Caspar I, Spahr L, et al.
Published in JHEP Reports 2021
Hepatocellular carcinoma is the most common type of liver cancer, increasingly arising in patients with NAFLD or MAFLD. S. Myers et al. (University of Geneva, Switzerland) assessed all patients with hepatocellular carcinoma between 1990 and 2014 in the canton of Geneva....
Read MoreNAFLD and MAFLD as emerging causes of hepatocellular carcinoma

Non-obese MAFLD is associated with colorectal adenoma

Authors: Fukunaga S, Nakano D, Kawaguchi T, et al.
Published in International Journal of Molecular Sciences 2021
Colorectal adenoma is linked to metabolic dysfunction. S. Fukunaga et al. (Kurume University School of Medicine, Japan) aimed to investigate the impact of MAFLD on the prevalence of colorectal adenoma by comparing it to NAFLD in health check-up examinees in a multicenter retrospective study....
Read MoreNon-obese MAFLD is associated with colorectal adenoma

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Authors: Pfister D, Núñez NG, Pinyol R, et al.
Published in Nature 2021
According to this article by D. Pfister et al. (German Cancer Research Center, Germany), the response to immunotherapy is better in patients with virus-induced HCC than in patients with non-viral HCC (that is, NASH). This might be due to the amount or quality of viral antigens....
Read MoreNASH limits anti-tumour surveillance in immunotherapy-treated HCC

NASH: bariatric surgery and major adverse liver and cardiovascular outcomes

Authors: Aminian A, Al-Kurd A, Wilson R, et al.
Published in JAMA 2021
In this retrospective cohort study of 1158 patients with biopsy-proven fibrotic NASH without cirrhosis, bariatric surgery was significantly associated with a lower risk of major adverse liver outcomes and major adverse cardiovascular events. For the authors, in this study....
Read MoreNASH: bariatric surgery and major adverse liver and cardiovascular outcomes

Pathogenesis of NASH and dynamic changes in liver macrophages

Authors: .
Published in .
Macrophage-mediated inflammation is critical in the pathogenesis of NASH. T-cell immunoglobulin domain and mucin domain-4 (TIM-4) is selectively expressed on antigen-presenting cells and modulates various immune responses. However, the role of TIM-4 expressed by Kupffer cells in liver fibrosis remains unclear....
Read MorePathogenesis of NASH and dynamic changes in liver macrophages

NAFLD: progressive liver fibrosis

Authors: Ramai D, Facciorusso A, Vigandt E, et al.
Published in Cells 2021
The progression of NASH was initially defined according to a two-hit model involving an initial development of steatosis, followed by a process of lipid peroxidation and inflammation. In contrast, current evidence proposes a "multi-hit" or "multi-parallel hit" model that includes multiple pathways....
Read MoreNAFLD: progressive liver fibrosis

NAFLD risk may be associated to dementia and cognitive decline in older age

Authors: Lampignano L, Donghia R, Griseta C, et al.
Published in Front Aging Neurosci 2021
The present study aimed to investigate the relationship between NAFLD risk and a dementia diagnosis in a large population-based sample aged >65 years. These findings suggest that “an increased NAFLD risk may be associated to dementia and cognitive decline in older age....
Read MoreNAFLD risk may be associated to dementia and cognitive decline in older age

Non-Invasive Evaluation of NAFLD Severity

Authors: https://player.vimeo.com/video/701904233
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are a leading cause of liver diseases worldwide, including hepatocellular carcinoma (HCC). In this review on non-invasive evaluation, Prof. Jérôme Boursier, France, presents a meta analysis focusing on the identification of patients with high risk profile and in need of specific management. Dr. Boursier reviews the two major families of non-invasive tests and discusses the sequential use of tests recommended in the EASL guidelines 2021.
Read MoreNon-Invasive Evaluation of NAFLD Severity

Advancing the global public health agenda for NAFLD

Authors: Lazarus JV, Mark HE, Anstee QM, et al.
Published in Nat Rev Gastroenterol Hepatol 2022
In this global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations. The resulting consensus statements and recommendations address a broad range of topics that have general relevance for policymakers, health-care practitioners, civil society groups, research institutions....
Read MoreAdvancing the global public health agenda for NAFLD

NASH: mobile health intervention for lifestyle modification

Authors: Faust A, Stine JG
Published in Dig Dis Sci 2021
Lifestyle modification designed to achieve sustained, modest weight loss remains hopelessly difficult to accomplish for many of patients with NAFLD. Mobile health application use to augment current educational practices will achieve meaningful dietary change and regular physical activity....
Read MoreNASH: mobile health intervention for lifestyle modification

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES